CELL-TARGETED BINARY ANTICANCER AGENTS

Information

  • Research Project
  • 3493000
  • ApplicationId
    3493000
  • Core Project Number
    R43CA056212
  • Full Project Number
    1R43CA056212-01
  • Serial Number
    56212
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/11/1992 - 34 years ago
  • Project End Date
    8/30/1992 - 34 years ago
  • Program Officer Name
  • Budget Start Date
    3/11/1992 - 34 years ago
  • Budget End Date
    8/30/1992 - 34 years ago
  • Fiscal Year
    1992
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/10/1992 - 34 years ago
Organizations

CELL-TARGETED BINARY ANTICANCER AGENTS

DESCRIPTION: (A dapted from the applicant's abstract) A novel method based on nontoxic components for targeting cancerous tissue is proposed. A binary system comprised of glucose oxidase and a metalloporphyrin conjugated to separate monoclonal antibodies (MAb) is targeted to a diseased cell. The juxtaposition of these components on the cell surface allows a cascade of actions to occur that ultimately kill the targeted cell.Glucose oxidase generates hydrogen peroxide from extracellular glucose and oxygen; the peroxide is activated into a reactive oxy intermediate by the metalloporphyrin. These intermediates react irreversibly with nearby biomolecules, such as cell membrane walls, which will destroy the cell. As this system is based on two catalytic components, combining a small amount of each compound will result in an amplified effect in the microenvironment of the cancerous tissue. Moreover, deleterious side effects in vivo due to high concentrations of chemotherapeutic agent will be reduced. In addition both enzyme and metalloporphyrin are nontoxic when kept separate, therefore nonspecific binding of a MAb conjugate will not damage healthy tissue. Initial studies will utilize lectins as the affinity carriers to show the viability of the proposed system; subsequent experiments will be carried out with MAbs.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ET
  • Study Section Name
    Experimental Therapeutics Subcommittee 2
  • Organization Name
    SYMBIOTECH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WALLINGFORD
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    06492
  • Organization District
    UNITED STATES